The biggest diabetes news to come out of ATTD 2022
FDA Approves Fiasp® For Use In Insulin Pumps for Adults with T1 and T2 Diabetes | dLife
Insulin 100 years
Abbott's diabetes deals • Sinai to close subacute unit • Medicare open enrollment | Crain's Chicago Business
Bionic pancreas improves type 1 diabetes management compared to standard insulin delivery methods | National Institutes of Health (NIH)
Nonprofit drugmaker will soon sell insulin for $30 a vial, regardless of insurance | WPMI
Global Insulin Pump Market Outlook and Forecast to 2028: Featuring Insulet, Medtronic, Tandem Diabetes Care, CeQur Simplicity and EOFLOW Among Others
A Technology Laggard's Foray into Insulin Pumps and Continuous Sensors
Researchers test an artificial pancreas in outpatients with type 2 diabetes
Guide to Insulin Pens
New Delivery Devices Make Taking Insulin Easier
Insulin pump therapy improves type 2 diabetes in poorly controlled patients, study reports - Diabetes
Diabetes Management Technologies 2022-2032: Markets, Players, and Forecasts: IDTechEx
With new Medtronic pact, Novo Nordisk's smart insulin pen to link with all major CGMs | Fierce Biotech
NOVO NORDISK: FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes | FDA Health News
NEWS: Medtronic Acquires InPen Smart Insulin Pen
Novo Nordisk Insulin Pen Certification | novoMEDLINK™
Diabetes Management with Insulin Pumps and CGMs (Continuous Glucose Monitors)
Treating Type 2 Diabetes | Medtronic
EU Approves Novo Nordisk's Pre-filled Insulin Cartridge for the New Accu-Chek Insight Insulin Pump
Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial - The Lancet Digital Health
Novo Nordisk and Roche' insulin pump system gets EU thumbs up
Frontiers | Real-World Application of Insulin Pump Therapy Among Patients With Type 1 Diabetes in China: A Cross-Sectional Study
Treating Type 2 Diabetes | Medtronic
